{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T04:42:08Z","timestamp":1782276128180,"version":"3.54.5"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf (UKE)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s00259-025-07237-8","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T22:55:43Z","timestamp":1743288943000},"page":"3613-3617","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Capacity for brain amyloid PET in Germany: Results from the 1st survey on nuclear brain imaging in Germany"],"prefix":"10.1007","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0945-0724","authenticated-orcid":false,"given":"R.","family":"Buchert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Drzezga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Schreckenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. T.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Working Group Nuclear Brain Imaging of the German Society of Nuclear Medicine (DGN e.V.)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"key":"7237_CR1","unstructured":"DGN e.V. & DGPPN e.V. (eds.). S3-Leitlinie Demenzen, Version 4.0. 08.11.2023."},{"key":"7237_CR2","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr","year":"2024","unstructured":"Jack CR Jr, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s association workgroup. Alzheimers Dement. 2024;20:5143\u201369. https:\/\/doi.org\/10.1002\/alz.13859.","journal-title":"Alzheimers Dement"},{"key":"7237_CR3","doi-asserted-by":"publisher","first-page":"e14338","DOI":"10.1002\/alz.14338","volume":"21","author":"GD Rabinovici","year":"2025","unstructured":"Rabinovici GD, Knopman DS, Arbizu J, Benzinger TLS, Donohoe KJ, Hansson O, et al. Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer\u2019s association and society for nuclear medicine and molecular imaging workgroup. Alzheimers Dement. 2025;21:e14338. https:\/\/doi.org\/10.1002\/alz.14338.","journal-title":"Alzheimers Dement"},{"key":"7237_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s43587-024-00630-2","author":"M Sarazin","year":"2024","unstructured":"Sarazin M, Lagarde J, El Haddad I, de Souza LC, Bellier B, Potier MC, et al. The path to next-generation disease-modifying immunomodulatory combination therapies in Alzheimer\u2019s disease. Nat Aging. 2024. https:\/\/doi.org\/10.1038\/s43587-024-00630-2.","journal-title":"Nat Aging"},{"issue":"48","key":"7237_CR5","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1007\/s00259-021-05485-y","volume":"I","author":"V Garibotto","year":"2021","unstructured":"Garibotto V, Albert NL, Barthel H, van Berckel B, Boellaard R, Brendel M, et al. The approval of a disease-modifying treatment for Alzheimer\u2019s disease: impact and consequences for the nuclear medicine community. Eur J Nucl Med Mol. 2021;I(48):3033\u20136. https:\/\/doi.org\/10.1007\/s00259-021-05485-y.","journal-title":"Eur J Nucl Med Mol"},{"key":"7237_CR6","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1007\/s00259-023-06177-5","volume":"50","author":"A Verger","year":"2023","unstructured":"Verger A, Yakushev I, Albert NL, van Berckel B, Brendel M, Cecchin D, et al. FDA approval of lecanemab: the real start of widespread amyloid PET use? - the EANM neuroimaging committee perspective. Eur J Nucl Med Mol Imaging. 2023;50:1553\u20135. https:\/\/doi.org\/10.1007\/s00259-023-06177-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7237_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07066-9","author":"I Yakushev","year":"2025","unstructured":"Yakushev I, Verger A, Brendel M, Cecchin D, Fernandez PA, Fraioli F, et al. Lecanemab approval in EU: what should we be ready for?- the EANM perspective. Eur J Nucl Med Mol Imaging. 2025. https:\/\/doi.org\/10.1007\/s00259-025-07066-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7237_CR8","unstructured":"European Medicines Agency. Leqembi, 14. November 2024, www.ema.europa.eu\/en\/medicines\/human\/EPAR\/leqembi, accessed 12. January 2025."},{"key":"7237_CR9","doi-asserted-by":"publisher","unstructured":"Lindner O, Schafer W, Rischpler C, Silber S, Burchert W, Working Group \"Cardiovascular Nuclear Medicine\" of the German Society for Nuclear M. Myocardial perfusion SPECT in Germany from 2012 to 2021: insights into development and quality indicators. Eur J Nucl Med Mol Imaging. 2023;50:1621-8.https:\/\/doi.org\/10.1007\/s00259-023-06129-z","DOI":"10.1007\/s00259-023-06129-z"},{"key":"7237_CR10","doi-asserted-by":"publisher","unstructured":"Canada's Drug Agency CDA-AMC. Health Technology Review: Health System Readiness for Disease-Modifying Therapies for Alzheimer Disease. Canadian Journal of Health Technologies. 2024;4. https:\/\/doi.org\/10.51731\/cjht.2024.1038.","DOI":"10.51731\/cjht.2024.1038"},{"key":"7237_CR11","unstructured":"Bowman Rogers M. Leqembi: Side Effects No Worse in Clinical Use Than They Were in Trial. Clinical Trials on Alzheimer's Disease (CTAD) 2024 - 17th, Part 3 of 12: ALZFORUM; accessed 11. January 2025."},{"key":"7237_CR12","doi-asserted-by":"publisher","unstructured":"Genin E, Hannequin D, Wallon D, Sleegers K, Hiltunen M, Combarros O, et al. and Alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatr. 2011;16:903\u20137. https:\/\/doi.org\/10.1038\/mp.2011.52.","DOI":"10.1038\/mp.2011.52"},{"key":"7237_CR13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1055\/a-1277-6014","volume":"60","author":"FD Juengling","year":"2021","unstructured":"Juengling FD, Allenbach G, Bruehlmeier M, Klaeser B, Wissmeyer MP, Garibotto V, et al. Appropriate use criteria for dementia amyloid imaging in Switzerland - mini-review and statement on behalf of the Swiss society of nuclear medicine and the Swiss memory clinics. Nuklearmed-Nucl Med. 2021;60:7\u20139. https:\/\/doi.org\/10.1055\/a-1277-6014.","journal-title":"Nuklearmed-Nucl Med"},{"key":"7237_CR14","doi-asserted-by":"crossref","unstructured":"Teipel SJ, Spottke A, Boecker H, Daamen M, Graf E, Sahlmann J, et al. Patient-related benefits of amyloid PET imaging in dementia: Rationale and design of the German randomized coverage with evidence development study ENABLE. Alzh Dement-Trci. 2023;9. ARTN e1238310.1002\/trc2.12383.","DOI":"10.1002\/trc2.12383"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07237-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07237-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07237-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T01:10:24Z","timestamp":1754356224000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07237-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":14,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["7237"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07237-8","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,27]]},"assertion":[{"value":"18 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval \/ Consent to participate"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}